Enzychem Lifesciences Corporation (183490.KQ)
KOSDAQ · KRW · Healthcare · Drug Manufacturers - Specialty & Generic
₩990 (+0.00%) as of
Key statistics
- Market cap
- 83.79B
- Dividend yield
- 0.00%
- 52-week range
- 966.00 – 1,766.00
- Beta
- 0.84
- Revenue (TTM)
- 69B
- Profit margin
- -26.08%
About Enzychem Lifesciences Corporation
Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Seoul, South Korea
- Employees
- 93
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.